Adverse effects after the use of JWH-210 : a case series from the EU Spice II plus project

Gespeichert in:
Bibliographische Detailangaben
Deutscher übersetzter Titel:Schädliche Auswirkungen der Einnahme von JWH-210 : eine Fallserie aus dem EU-Projekt „Spice II Plus“
Autor:Hermanns-Clausen, Maren; Kithinji, Josephine; Spehl, Marco; Angerer, Verena; Franz, Florian; Eyer, Florian; Auwärter, Volker
Erschienen in:Drug testing and analysis
Veröffentlicht:8 (2016), 9/10, S. 1030-1038, Lit.
Format: Literatur (SPOLIT)
Publikationstyp: Zeitschriftenartikel
Medienart: Elektronische Ressource (online) Gedruckte Ressource
Sprache:Englisch
ISSN:1942-7603, 1942-7611
DOI:10.1002/dta.1936
Schlagworte:
Online Zugang:
Erfassungsnummer:PU201611008027
Quelle:BISp

Abstract des Autors

Since 2009, more than 140 different synthetic cannabinoids (SC) have been identified in herbal mixtures consumed as recreational drugs. Knowledge of the acute toxicity of each individual compound remains sparse. Here we present a retrospective observational case series of patients presenting to emergency departments with analytically confirmed intake of JWH-210 as the only SC detected in serum samples. Cases were selected from a poison centre database from March 2011 to June 2014. In total, 22 patients were included (aged 12–25 years, median 17.5; 18 males 4 female). JWH-210 was identified in the serum samples in concentrations ranging from 0.18 to 90 ng/mL. Tachycardia, nausea, somnolence, hypokalemia, hypertension, restlessness, and/or agitation were most frequently reported. Diplopia, seizures, syncope, and ECG changes such as T-wave inversion and bradycardia were also noted. Acute adverse effects of JWH-210 typically include central nervous system depression or cerebral seizures, but also signs of sympathomimetic toxicity. Nausea was reported in 80% and typically shows a sudden onset shortly after inhalation, suggesting a central nervous effect possibly mediated by CB1 receptors. Cardiovascular effects are reported in up to 80% of the patients and might not only include alterations in blood pressure and heart rate, but also changes in the electrocardiogram (ECG). JWH-210 as a representative of a strong CB1 receptor agonist confirms previous reports about adverse effects of SC, but shows a distinct quantitative pattern of symptoms, compared to several other SC.